Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK

Shrikrishnapalasuriyar, Natasha; Shaikh, Ayesha; Ruslan, Aliya Mohd; Sharaf, Giselle; Udiawar, Maneesh; Price, David E.; Stephens, Jeffrey W.

doi:10.1016/j.dsx.2020.03.007

Cited by 3 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The protective mechanism of SGLT2i on the cardiovascular system involves many aspects, including direct and indirect effects on the heart, which are summarized as follows (Table 4) [40][41][42][43][44][45].…”

Section: Protective Effect Of Sglt2i On the Cardiovascular Systemmentioning

confidence: 99%

SGLT2i: beyond the glucose-lowering effect

Yuan

Chen

et al. 2020

Cardiovasc Diabetol

139

115

View full text Add to dashboard Cite

Sodium/glucose cotransporter-2 inhibitors (SGLT2i) are a new type of glucose-lowering drug that can reduce blood glucose by inhibiting its reabsorption in proximal tubules and by promoting urinary glucose excretion. SGLT2i are widely used in the clinical treatment of type 2 diabetes mellitus (T2DM). In recent studies, SGLT2i were found to not only reduce blood glucose but also protect the heart and kidney, which can significantly reduce cardiovascular events, delay the progression of renal failure, greatly improve the quality of life of patients, and reduce medical expenses for families and society. As adverse cardiac and renal events are the most common and serious complications of T2DM, it is very important to understand the cardio- and renoprotective mechanisms of SGLT2i. This article reviews the historical development, pharmacological mechanism, heart and kidney protection and safety of SGLT2i. The information presented provides a theoretical basis for the clinical prevention and treatment of diabetes and its complications and for the development of new glucose-lowering drugs.

show abstract

Section: Protective Effect Of Sglt2i On the Cardiovascular Systemmentioning

confidence: 99%

SGLT2i: beyond the glucose-lowering effect

Yuan

Chen

et al. 2020

Cardiovasc Diabetol

139

115

View full text Add to dashboard Cite

show abstract

Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events

Matos

Calado

Washburn

et al. 2021

Successful Drug Discovery

View full text Add to dashboard Cite

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics

Liu¹,

Ma²,

Ilyas³

et al. 2021

Theranostics

View full text Add to dashboard Cite

Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are new oral drugs for the therapy of patients with type 2 diabetes mellitus (T2DM). Research in the past decade has shown that drugs of the SGLT2i class, such as empagliflozin, canagliflozin, and dapagliflozin, have pleiotropic effects in preventing cardiovascular diseases beyond their favorable impact on hyperglycemia. Of clinical relevance, recent landmark cardiovascular outcome trials have demonstrated that SGLT2i reduce major adverse cardiovascular events, hospitalization for heart failure, and cardiovascular death in T2DM patients with/without cardiovascular diseases (including atherosclerotic cardiovascular diseases and various types of heart failure). The major pharmacological action of SGLT2i is through inhibiting glucose re-absorption in the kidney and thus promoting glucose excretion. Studies in experimental models of atherosclerosis have shown that SGLT2i ameliorate the progression of atherosclerosis by mechanisms including inhibition of vascular inflammation, reduction in oxidative stress, reversing endothelial dysfunction, reducing foam cell formation and preventing platelet activation. Here, we summarize the anti-atherosclerotic actions and mechanisms of action of SGLT2i, with an aim to emphasize the clinical utility of this class of agents in preventing the insidious cardiovascular complications accompanying diabetes.

show abstract

Dapagliflozin is associated with improved glycaemic control and weight reduction at 44 months of follow-up in a secondary care diabetes clinic in the UK

Cited by 3 publications

References 13 publications

SGLT2i: beyond the glucose-lowering effect

SGLT2i: beyond the glucose-lowering effect

Recent Advances on SGLT 2 Inhibitors: Synthetic Approaches, Therapeutic Benefits, and Adverse Events

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: from pharmacology to pre-clinical and clinical therapeutics

Contact Info

Product

Resources

About